Microfluidic chip tracks cancer relapse by measuring white blood cell adhesion

AI Summary

Researchers at UNIST have developed a microfluidic diagnostic chip that measures white blood cell adhesion properties to detect cancer recurrence and assess chemotherapy effectiveness. Led by Professor Joo Hun Kang, the technology represents a novel approach to cancer monitoring using immune cell behavior. The innovation could transform how oncologists track disease relapse and treatment response.

A new microfluidic technology that leverages immune cell behavior is set to transform cancer monitoring, thanks to researchers at UNIST. Led by Professor Joo Hun Kang in the Department of Biomedical Engineering at UNIST, the team has introduced a novel diagnostic chip that analyzes the adhesion properties of leukocytes, or white blood cells, to detect cancer recurrence and evaluate the effectiveness of chemotherapy.